| Name | Title | Contact Details |
|---|
Catholic Charities CYO is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Catholic Charities CYO is based in San Francisco, CA. You can find more information on Catholic Charities CYO at www.cccyo.org
Moore Medical Corp. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Farmington, CT. To find more information about Moore Medical Corp., please visit www.mooremedical.com
Park Place Behavioral Health Care is a Kissimmee, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Southwest General is a 350-bed, non-profit hospital serving southwestern Cuyahoga, northern Medina and eastern Lorain counties. Founded in 1920 by residents of the surrounding communities, Southwest General has a rich history of community partnership and a deep commitment to the health and well-being of the residents it serves. Southwest General is home to nationally recognized physicians, state-of-the-art technology and a full range of medical, surgical and emergency services, including a Level III trauma center. Additionally, patients and families benefit from an extensive program of social services and support groups that provide mental, emotional and spiritual support. All services at Southwest General are provided with an eye toward excellence and individual attention. This is best expressed in Southwest General`s mission statement: Health is our Passion. Quality is our Focus. Compassion is our Way.
Surface Oncology is a clinical-stage immuno-oncology company focused on using its specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment (TME) for the development of next-generation therapies to help patients suffering with cancer. Recent advances in understanding how the immune system fights cancer has created a first wave of immunotherapies with profound benefits for some patients. These first-generation therapies, or "checkpoint inhibitors", have been groundbreaking, but only a relatively small subset of patients is deriving long-term benefit. We believe that the lack of a broad and sustained clinical response is because these first-generation therapies only target one component of the immunosuppressive TME and a broader, more multi-faceted therapeutic approach is required. We are a team on a mission to deliver transformative outcomes for people with cancer by breaking through the frontiers of immuno-oncology research. Our diverse clinical and preclinical pipeline of immune-enhancing antibody candidates target the innate and adaptive arms of the immune system to deliver dramatically different therapies for patients and their families. Surface is leveraging its deep understanding of TME biology to target factors and cells that suppress patients’ anti-tumor immune response. Our broad attack on the TME has the potential to convert patients’ non-responsive ‘cold’ tumors into immune-active ones. We push ourselves to break through across all dimensions of our work. From a discovery perspective, Surface leverages its world-class SAB to identify new targets and takes an aggressive approach towards generating diverse, highly-specific antibodies, which allows our scientists to thoroughly explore the relevant biology. Our antibody discovery approach generates therapeutic-quality antibodies, as well as unique tools to explore the biology of the tumor microenvironment.